Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 147 No. 2728 (2017)

Adherence to osteoporosis pharmacotherapy one year after osteoporotic fracture – a Swiss trauma centre secondary prevention project

DOI
https://doi.org/10.4414/smw.2017.14451
Cite this as:
Swiss Med Wkly. 2017;147:w14451
Published
10.07.2017

Summary

AIMS OF THE STUDY

According to current evidence, one out of ten fracture patients with osteoporosis does not sustain another fracture if he or she is on adequate medication. However, epidemiological surveys show that only about 15 to 30% of affected patients avail themselves of the treatments. This cohort study investigated how many fracture patients with a recommendation for antiosteoporotic therapy effectively received treatment and the possible reasons why the treatment was not implemented.

METHODS

As part of a quality improvement programme in a Swiss trauma centre, fracture patients were actively checked for osteoporosis in accordance with a standardised outpatient programme. The results, together with detailed therapy recommendations, were transmitted to each patient’s general practitioner (GP). A prospective questionnaire survey evaluated all patients with a diagnosis of osteoporosis for subsequent realisation of therapy 1 year after the fracture (mean ± standard deviation; chi-square; analysis of variance; significance level p <0.05).

RESULTS

A total of 305 patients received a recommendation for antiosteoporotic therapy, of whom 18 (5.9%) died before 1 year. The questionnaire was completed for 255 out of 287 patients (follow-up 88.9%; 73.8±11.5 years old at the time of survey; 77.7% female). Of these, 117 patients (45.9%) sustained a fracture of the lower extremities and 105 patients (41.1%) a fracture of the upper extremities; 33 patients (13%) had other or multiple fractures. Fifty-two cases (20.4%) had pre-existing osteoporosis at the time of fracture. At the 1-year follow-up, 132 (52%) patients were receiving prescribed drugs. The most frequent patient explanation for not taking treatment (n = 123) was, in 47.2% of cases (n = 58), that none had been prescribed; 30.1% of patients were not interested. Multivariate analysis of verifiable factors of influence confirmed that fracture patients were treated significantly more reliably with antiosteoporotic therapy if osteoporosis was diagnosed with dual energy x-ray absorptiometry alone in patients with fewer comorbidities, and that fracture patients persisted significantly more reliably with antiosteoporotic therapies when pre-existing osteoporosis was present (R2 0.17; p <0.001).

CONCLUSIONS

Following a standardised diagnostic work up for osteoporosis as part of fracture treatment, and including the communication of recommendations for antiosteoporotic therapy to the GP, only every second patient actually received the proposed treatment. This appears to be better than described in the literature but still calls for improvement. Two different solutions appear to be possible based on these findings: to endeavour to better inform and convince GPs about the need for treatment and/or for the diagnosing team to initiate antiosteoporotic therapy where indicated rather than just recommending it.

References

  1. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90(1):107–10. https://doi.org/10.1016/0002-9343(91)90512-V
  2. Lippuner K. Epidémiologie des fractures ostéoporotiques en Suisse. [Epidemiology of osteoporotic fractures in Switzerland]. Rev Med Suisse. 2009;5(207):1304–8.
  3. Adler RA. Secondary fracture prevention. Curr Osteoporos Rep. 2012;10(1):22–7. https://doi.org/10.1007/s11914-011-0090-z
  4. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010;95(3):1174–81. https://doi.org/10.1210/jc.2009-0852
  5. Grey A, Bolland MJ. The effect of treatments for osteoporosis on mortality. Osteoporos Int. 2013;24(1):1–6. https://doi.org/10.1007/s00198-012-2176-6
  6. Hochberg M. Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging. 2000;17(4):317–30. https://doi.org/10.2165/00002512-200017040-00007
  7. Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008;19(1):79–86. https://doi.org/10.1007/s00198-007-0426-9
  8. Dell RM, Greene D, Anderson D, Williams K. Osteoporosis disease management: What every orthopaedic surgeon should know. J Bone Joint Surg Am. 2009;91(Suppl 6):79–86. https://doi.org/10.2106/JBJS.I.00521
  9. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35(5):293–305. https://doi.org/10.1016/j.semarthrit.2005.11.001
  10. Leslie WD, Giangregorio LM, Yogendran M, Azimaee M, Morin S, Metge C, et al. A population-based analysis of the post-fracture care gap 1996-2008: the situation is not improving. Osteoporos Int. 2012;23(5):1623–9. https://doi.org/10.1007/s00198-011-1630-1
  11. Papaioannou A, Giangregorio L, Kvern B, Boulos P, Ioannidis G, Adachi JD. The osteoporosis care gap in Canada. BMC Musculoskelet Disord. 2004;5(1):11. https://doi.org/10.1186/1471-2474-5-11
  12. Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003;115(5):398–400. https://doi.org/10.1016/S0002-9343(03)00357-7
  13. Kanis JA, Adams J, Borgström F, Cooper C, Jönsson B, Preedy D, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008;42(1):4–15. https://doi.org/10.1016/j.bone.2007.10.019
  14. Ziller V, Kostev K, Kyvernitakis I, Boeckhoff J, Hadji P. Persistence and compliance of medications used in the treatment of osteoporosis--analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther. 2012;50(5):315–22. https://doi.org/10.5414/CP201632
  15. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23(1):223–31. https://doi.org/10.1007/s00198-011-1535-z
  16. Majumdar SR. Quality-improvement interventions for osteoporosis: when are the results worth the effort? CMAJ. 2012;184(3):279–80. https://doi.org/10.1503/cmaj.111999
  17. Majumdar SR, Johnson JA, McAlister FA, Bellerose D, Russell AS, Hanley DA, et al. Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. CMAJ. 2008;178(5):569–75. https://doi.org/10.1503/cmaj.070981
  18. Suhm N, Lamy O, Lippuner K ; OsteoCare study group. Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly. 2008;138(45-46):674–83.
  19. Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S, et al. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporos Int. 2007;18(3):261–70. https://doi.org/10.1007/s00198-006-0248-1
  20. Rosenwasser MP, Cuellar D. Medical management of osteoporosis and the surgeons’ role. Injury. 2016;47(Suppl 1):S62–4. https://doi.org/10.1016/S0020-1383(16)30014-6
  21. Haasters F, Prall WC, Himmler M, Polzer H, Schieker M, Mutschler W. [Prevalence and management of osteoporosis in trauma surgery. Implementation of national guidelines during inpatient fracture treatment]. Unfallchirurg. 2015;118(2):138–45. https://doi.org/10.1007/s00113-013-2500-4
  22. Chevalley T, Hoffmeyer P, Bonjour JP, Rizzoli R. An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int. 2002;13(6):450–5. https://doi.org/10.1007/s001980200053
  23. Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O’Malley CD. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am. 2014;96(7):e52, 1–8. https://doi.org/10.2106/JBJS.L.01781
  24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8
  25. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al.; National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81. https://doi.org/10.1007/s00198-014-2794-2
  26. Parikh S, Mogun H, Avorn J, Solomon DH. Osteoporosis medication use in nursing home patients with fractures in 1 US state. Arch Intern Med. 2008;168(10):1111–5. https://doi.org/10.1001/archinte.168.10.1111
  27. Vogel T, Kampmann P, Bürklein D, Böhm H, Ockert B, Kirchhoff C, et al. [Reality of treatment of osteoporotic fractures in German trauma departments. A contribution for outcome research]. Unfallchirurg. 2008;111(11):869–77. https://doi.org/10.1007/s00113-008-1504-y
  28. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011;22(7):2083–98. https://doi.org/10.1007/s00198-011-1534-0
  29. Sale JE, Beaton D, Posen J, Elliot-Gibson V, Bogoch E. Key outcomes are usually not reported in published fracture secondary prevention programs: results of a systematic review. Arch Orthop Trauma Surg. 2014;134(2):283–9. https://doi.org/10.1007/s00402-011-1442-y
  30. Svedbom A, Ivergård M, Hernlund E, Rizzoli R, Kanis JA. Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos. 2014;9(1):187. https://doi.org/10.1007/s11657-014-0187-y
  31. Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B, et al. Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am. 2014;96(4):e29. https://doi.org/10.2106/JBJS.L.00223
  32. Gleeson T, Iversen MD, Avorn J, Brookhart AM, Katz JN, Losina E, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int. 2009;20(12):2127–34. https://doi.org/10.1007/s00198-009-0976-0
  33. Solomon DH, Iversen MD, Avorn J, Gleeson T, Brookhart MA, Patrick AR, et al. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med. 2012;172(6):477–83. https://doi.org/10.1001/archinternmed.2011.1977
  34. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;(11):CD000011.
  35. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY ; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57. https://doi.org/10.1007/s00198-012-2074-y
  36. Breuil V, Cortet B, Cotté FE, Arnould B, Dias-Barbosa C, Gaudin A-F, et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int. 2012;23(2):445–55. https://doi.org/10.1007/s00198-011-1555-8
  37. Sale JE, Beaton D, Bogoch E. Secondary prevention after an osteoporosis-related fracture: an overview. Clin Geriatr Med. 2014;30(2):317–32. https://doi.org/10.1016/j.cger.2014.01.009
  38. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195–202. https://doi.org/10.1016/j.bone.2003.10.001
  39. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, et al.; Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787–93. https://doi.org/10.1210/jc.2004-1568
  40. Chenot R, Scheidt-Nave C, Gabler S, Kochen MM, Himmel W. German primary care doctors’ awareness of osteoporosis and knowledge of national guidelines. Exp Clin Endocrinol Diabetes. 2007;115(9):584–9. https://doi.org/10.1055/s-2007-981454
  41. Edwards BJ, Koval K, Bunta AD, Genuario K, Hahr A, Andruszyn L, et al. Addressing secondary prevention of osteoporosis in fracture care: follow-up to “own the bone”. J Bone Joint Surg Am. 2011;93(15):e87. https://doi.org/10.2106/JBJS.I.00540
  42. Sale JE, Bogoch E, Hawker G, Gignac M, Beaton D, Jaglal S, et al. Patient perceptions of provider barriers to post-fracture secondary prevention. Osteoporos Int. 2014;25(11):2581–9. https://doi.org/10.1007/s00198-014-2804-4
  43. Giusti A, Barone A, Razzano M, Oliveri M, Pizzonia M, Palummeri E, et al. Persistence with calcium and vitamin D in elderly patients after hip fracture. J Bone Miner Metab. 2009;27(1):95–100. https://doi.org/10.1007/s00774-008-0007-9
  44. Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414–9. https://doi.org/10.1001/archinte.165.20.2414
  45. Gruber-Baldini AL, Zimmerman S, Morrison RS, Grattan LM, Hebel JR, Dolan MM, et al. Cognitive impairment in hip fracture patients: timing of detection and longitudinal follow-up. J Am Geriatr Soc. 2003;51(9):1227–36. https://doi.org/10.1046/j.1532-5415.2003.51406.x
  46. Mauck KF, Cuddihy MT, Trousdale RT, Pond GR, Pankratz VS, Melton LJ, 3rd. The decision to accept treatment for osteoporosis following hip fracture: exploring the woman’s perspective using a stage-of-change model. Osteoporos Int. 2002;13(7):560–4. https://doi.org/10.1007/s001980200073
  47. Zarowitz BJ, Cheng LI, Allen C, O’Shea T, Stolshek B. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis. J Am Med Dir Assoc. 2015;16(4):341–8. https://doi.org/10.1016/j.jamda.2015.01.073
  48. Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, et al. Persistance and compliance with osteroporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm. 2015;21(9):824–33, 833a. https://doi.org/10.18553/jmcp.2015.21.9.824
  49. Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord. 2010;11(4):275–80. https://doi.org/10.1007/s11154-010-9138-0
  50. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493–501. https://doi.org/10.1016/S0025-6196(11)61093-8
  51. O’Neill TW, Marsden D, Matthis C, Raspe H, Silman AJ. Survey response rates: national and regional differences in a European multicentre study of vertebral osteoporosis. J Epidemiol Community Health. 1995;49(1):87–93. https://doi.org/10.1136/jech.49.1.87